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The Journal of Immunology
IL-15 Promotes Polyfunctional NK Cell Responses to
Influenza by Boosting IL-12 Production
Helen R. Wagstaffe,* Carolyn M. Nielsen,*,† Eleanor M. Riley,*,‡ and Martin R. Goodier*
IL-15 is a key regulator of NK cell maintenance and proliferation and synergizes with other myeloid cell–derived cytokines to
enhance NK cell effector function. At low concentrations, trans-presentation of IL-15 by dendritic cells can activate NK cells,
whereas at higher concentrations it can act directly on NK cells, independently of accessory cells. In this study, we investigate the
potential for IL-15 to boost responses to influenza virus by promoting accessory cell function. We find that coculture of human
PBMCs with inactivated whole influenza virus (A/Victoria/361/2011) in the presence of very low concentrations of IL-15 results in
increased production of myeloid cell–derived cytokines, including IL-12, IFN-a2, GM-CSF, and IL-1b, and an increased fre-
quency of polyfunctional NK cells (defined by the expression of two or more of CD107a, IFN-g, and CD25). Neutralization
experiments demonstrate that IL-15–mediated enhancement of NK cell responses is primarily dependent on IL-12 and partially
dependent on IFN-abR1 signaling. Critically, IL-15 boosted the production of IL-12 in influenza-stimulated blood myeloid
dendritic cells. IL-15 costimulation also restored the ability of less-differentiated NK cells from human CMV-seropositive indi-
viduals to respond to influenza virus. These data suggest that very low concentrations of IL-15 play an important role in boosting
accessory cell function to support NK cell effector functions. The Journal of Immunology, 2018, 200: 000–000.
I
nterleukin-15 is essential for the survival, proliferation, and
functional integrity of NK cells and is being exploited to
enhance NK cell–mediated immunotherapies (1, 2). IL-15
augments NK cell expression of perforin, granzyme B, natural
cytotoxicity receptors NKp30 and NKp44 (3), and the activating
receptor NKG2D (4). The potency of IL-15, even at very low
concentrations, is due, in part, to its presence as a complex with
the a-chain of its own receptor (IL-15Ra) at the surface of APCs
(5), where it can be presented to the same cell (cis-presentation) or
to neighboring cells (trans-presentation), such as NK cells and
CD8+ T cells that express IL-15Rb and the common g-chain re-
ceptor (IL-15Rbgc) (6).
Dendritic cells (DCs) can be induced to present IL-15 at their
surface by microbial ligands signaling through TLR and by innate
cytokines, such as GM-CSF and type I IFN (7, 8). DC-mediated
NK cell activation is dependent, in part, on IL-15 that polarizes to
the DC–NK cell synapse during conjugate formation (9). Although
IL-15 is believed to mediate the majority of its effects via trans-
presentation by IL-15Ra, at high concentrations it can bind di-
rectly to IL-15Rbgc and, thereby, activate NK cells (10). Furthermore,
at very high concentrations, free IL-15 may bind to IL-15Ra
on neighboring cells for cis- or trans-presentation (5, 11). Low
concentrations of IL-15 alone induce negligible NK cell acti-
vation, but IL-15 is highly synergistic with other cytokines and
with recall Ags, such as influenza, for NK cell CD25 and IFN-g
expression (12, 13).
IL-15 trans-presentation is being explored for cancer im-
munotherapy; induction of constitutive expression of IL-15 and
IL-15Ra by DCs or the use of soluble IL-15/IL-15Ra complexes
has been shown to enhance NK cell antitumor activity in vitro and
in preclinical mouse studies (reviewed in Ref. 14). Another
strategy for NK cell immunotherapy includes activation of NK
cells with IL-12, IL-15, and IL-18 prior to adoptive transfer, which
reduces tumor growth in mice (15). Preactivation of PBMCs with
high concentrations of IL-15 can also restore impaired NK cell
cytotoxicity of SIV-infected macaques (16). Although these
studies are consistent with direct NK cell priming by IL-15 at high
concentration, or synergy with myeloid cell–derived cytokines at
low concentration, the potential for IL-15 to amplify the myeloid
cell response has not been thoroughly explored. However, one
study has shown that TLR-induced maturation of DCs is enhanced
in the presence of IL-15, leading to increased NK cell cytotoxicity
toward human papillomavirus (HPV)-infected cells (17).
We hypothesized that, in addition to NK cell activation by trans-
presentation and other direct effects, IL-15 could have indirect
effects on the response of human NK cells to viruses by promoting
NK cell–activating cytokines from accessory cells. We show that
very low concentrations of IL-15 (0.75 ng/ml) dramatically en-
hance the production of IL-12, IFN-a, IL-1b, and GM-CSF from
myeloid accessory cells in response to inactivated whole influenza
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virus (A/Victoria/361/2011) (H3N2) and that increased production
of IFN-a and, in particular, IL-12 is associated with heightened
and sustained activation of NK cells and polyfunctionality of the
responding NK cells. Furthermore, IL-15–mediated enhancement
preferentially boosts IL-12 production in myeloid DCs (mDCs)
compared with other blood DC populations and monocytes. These
studies suggest that IL-15–enhanced accessory cell function may
potentiate NK cell responses, providing an additional avenue of
interest for boosting NK cell effector responses in vaccination and
NK cell–mediated immunotherapy.
Materials and Methods
Study participants
Volunteers were recruited from the staff and students at the London School
of Hygiene and Tropical Medicine (n = 84) using an anonymized volunteer
database. The study was approved by the London School of Hygiene and
Tropical Medicine Research Ethics Committee (reference numbers 6237
and 6324). Human CMV (HCMV) serostatus was determined for each
donor with HCMV IgG ELISA (Biokit, Barcelona, Spain) using plasma
collected from heparinized whole blood. Donors ranged in age from 20 to
77 y, with a median age of 32 y. Twenty-nine (35%) of the donors were
male, and 48% were HCMV seropositive.
PBMC isolation and in vitro culture assays
PBMCswere isolated from heparinized whole blood using Histopaque 1077
(Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. Cells were
rested for 2 h and were used fresh (blocking experiments and IL-12 in-
tracellular staining) or were cryopreserved in liquid nitrogen (all other
experiments). Before use, frozen cells were thawed and washed in RPMI
1640 supplemented with 100 U/ml penicillin/streptomycin and 20 mM L-
glutamine (Life Technologies, Thermo Fisher). Cells were counted using a
Countess II FL Automated Cell Counter (Invitrogen, Thermo Fisher);
average viability after thaw was 86%. A total of 3 3 105 cells per well was
cultured in RPMI 1640 supplemented as above with 5% pooled human AB
serum for 6, 9, or 18 h at 37˚C in 96-well round-bottom plates with 2 mg/ml
H3N2 (IVR-165; National Institute for Biological Standards and Control,
Potters Bar, U.K.), with or without 0.75 ng/ml recombinant human IL-15
(PeproTech, London, U.K.). Concentrations were determined by prior ti-
tration; 2 mg/ml H3N2 was the lowest concentration to induce significant
NK cell IFN-g upregulation without the presence of additional cytokines,
and 0.75 ng/ml IL-15 was previously shown to be the lowest concentration
to synergize with other cytokines for NK cell activation, without significant
NK cell activation alone (13). Additional cultures were stimulated with a
high concentration of cytokines consisting of IL-12 (5 ng/ml; PeproTech)
and IL-18 (50 ng/ml; R&D Systems, Oxford U.K.). The following Abs
were used for blocking experiments: anti–IL-2 (3 mg/ml; BD Biosciences,
Oxford, U.K.), rat IgG2a isotype control (3 mg/ml; eBioscience, Thermo
Fisher), anti–IL-12 (3 mg/ml; BD Biosciences), anti–IFN-abR2 (1 mg/ml;
Merck Millipore, Watford, U.K.), and combined mouse IgG1 and IgG2a
isotype controls (3 mg/ml final; eBioscience). GolgiStop (monensin; 1/
1500 concentration) and GolgiPlug (brefeldin A; 1/1000 final concentra-
tion; both from BD Biosciences) were added for the final 3 h of culture.
Culture supernatants were collected and stored at 280˚C. For control
experiments, NK cells were purified (mean purity 87%) using an NK Cell
Isolation Kit (Miltenyi Biotec), and 2 3 105 cells were stimulated for 18 h
under the conditions described above for PBMC cultures. Cells were stained
with NK cell activation markers as before. For IL-12 intracellular staining
experiments, 2 3 106 cells per well were cultured as above for 18 h, with
GolgiStop and GolgiPlug for the final 5 h.
Flow cytometry and Luminex
Cells were stained in 96-well round-bottom plates for surface markers,
including viability marker (Fixable Viability Dye eFluor 780; eBioscience)
in FACS buffer (PBS containing 0.5% FCS, 0.05% sodium azide, and 2 mM
EDTA) for 30 min after blocking Fc receptors for 5 min with Fc Receptor
Blocking Reagent (Miltenyi Biotec). Cells were then washed in FACS
buffer and fixed and permeabilized using a BD Cytofix/Cytoperm Kit,
according to the manufacturer’s instructions. Cells were then stained for
intracellular markers with FcR blocking for 15 min and washed again;
finally, cells were resuspended in 300 ml of FACS buffer and transferred to
alpha tubes for acquisition on a BD LSR II flow cytometer. The following
fluorophore-labeled Abs were used: anti-CD3–V500 (clone UCHT1), anti-
CD56–PE–Cy7 (clone NCAM16.2), anti-CD107a–FITC (clone H4A3),
anti-HLA-DR–PE (clone TU36) (all from BD Biosciences), anti-
IFN-g–allophycocyanin (clone 45.B3), anti-CD86–Alexa Fluor 488 (clone
IT2.2), anti-CD11c–PerCP-Cy5.5 (clone 3.1), anti-CD16–PE/Dazzle (clone
3G8), anti-CD14–Alexa Fluor 700 (clone 63D3) (all from BioLegend,
London, U.K.), anti-CD25–PerCP-Cy5.5 (clone BC96), anti-CD57–eFluor
450 (clone TB01), anti-CD19–PE–Cy5 (clone HIB19), anti-CD123–eFluor
450 (clone 6H6), and anti–IL-12(p40)–eFluor 660 (clone C17.8) (all from
eBioscience). Cells were acquired using FACSDiva software, and data
were analyzed using FlowJo v10 (TreeStar, Ashland, OR). FACS gates
were set using unstimulated cells or fluorescence minus one controls, and
samples with ,100 NK cell events were excluded. Concentrations of GM-
CSF, IFN-a2, IFN-g, TNF-a, IP-10, IL-1b, IL-10, and IL-12p70 in cell
culture supernatants were determined using Luminex technology (Merck
Millipore) and Bio-Plex software (Bio-Rad, Watford, U.K.).
Statistics
Statistical analysis was performed using GraphPad Prism version 7.01
(GraphPad, La Jolla, CA). Functional responses were compared using the
Wilcoxon signed-rank test, and intergroup comparisons between HCMV-
seropositive and HCMV-seronegative individuals were performed using
the Mann–Whitney U test. Correlation analysis was performed using linear
regression. Significance levels are assigned as *p , 0.05, **p , 0.01,
***p , 0.001, and ****p , 0.0001 for all tests. Analysis and presentation
of polyfunctional NK cell data were performed using SPICE version 5.1
(downloaded from https://niaid.github.io/spice/).
Results
Nanogram concentrations of IL-15 boost and sustain
functional NK cell responses to H3N2
To determine the effect of a low concentration of exogenous IL-15
on the frequency and kinetics of NK cell responses to influenza,
IFN-g, CD107a, and CD25 were measured at 6, 9, and 18 h after
stimulation of human PBMCs with H3N2 in the presence or ab-
sence of 0.75 ng/ml recombinant human IL-15. The flow cytom-
etry gating strategy is shown in Fig. 1A–D. H3N2 alone induced
high frequencies of NK cells expressing each of the three acti-
vation markers, but there was no significant response to IL-15
alone. At all time points, the percentage of expression of all
markers was significantly higher when cells were cultured with
H3N2 plus IL-15 compared with cells cultured with H3N2 alone
(Fig. 1E–G), with each marker displaying distinctly different ki-
netics (frequencies of cells expressing CD107a, IFN-g, and CD25
peaking at 6, 9, and 18 h, respectively). A low frequency of NK
cells showed spontaneous degranulation (CD107a expression) at
early time points (Fig. 1E), whereas there was little or no IFN-g
production or CD25 induction in unstimulated cultures (Fig. 1F, 1G).
Increased responses to H3N2 in the presence of IL-15 were re-
flected in increased mean fluorescence intensities (MFIs) for all
NK cell functional markers at their optimal time points. A small,
but significant, increase was observed in CD107a MFI at 6 h
(H3N2 median 747 units, interquartile range [IQR] 718–776;
H3N2+IL-15 median 768 units, IQR 735–813, p# 0.0001), IFN-g
MFI increased substantially by 9 h (H3N2 median 681 units, IQR
523–814; H3N2+IL-15 median 1037 units, IQR 864–1179, p #
0.0001), and a significant shift in CD25 MFI was observed by 18 h
(H3N2 median 72.5 units, IQR 34.7–153.8; H3N2+IL-15 median
371.5 units, IQR 249–508, p # 0.0001). Thus, very low concen-
trations of IL-15 boost the NK cell response to H3N2 stimulation
and lead to sustained CD107a and IFN-g production compared
with untreated cultures.
NK cells are a heterogeneous population of cells; CD56bright
subsets are highly responsive to cytokines, whereas the more
mature CD56dimCD57+ subset is known to be less responsive to
cytokines but maintains cytotoxic function (18). Therefore, we
analyzed the response of each of these subsets to IL-15 (flow
cytometry gating strategy shown in Supplemental Fig. 1A). As
expected, the early degranulation response was highest in the
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most mature (CD56dimCD57+) subset and IFN-g production was
highest in the less mature (CD56dimCD572) subsets at the peak of each
response (Supplemental Fig. 1B, 1F). However, at 6 h, IL-15 had little
effect on degranulation in the CD56dimCD57+ NK cell population,
whereas, by 9 h, the heightened response in the presence of IL-15 was
pronounced within the CD56bright and CD56dim subsets (Supplemental
Fig. 1B, 1E). Enhancement of NK cell IFN-g and CD25 responses to
influenza by low concentrations of IL-15 was evident to a similar
extent in all NK cell subsets (Supplemental Fig. 1C–J).
IL-15 enhances NK cell polyfunctionality
Because IL-15 appeared to enhance all three NK cell functions to a
similar degree, we considered the possibility that this was due to a
fraction of NK cells being highly sensitive to the effects of IL-15
and responding in a polyfunctional manner. We examined coex-
pression of IFN-g with CD107a, CD25, or both at each time point
(flow cytometry gating strategy shown in Fig. 2A–C). No poly-
functional NK cells were detected in unstimulated cultures or in
cultures containing only IL-15 (Supplemental Fig. 2A–C). When
cells were cultured with H3N2 alone, very few double- or triple-
positive NK cells were detectable (Fig. 2D–F); however, after 6 or
9 h of culture with H3N2 plus IL-15, a considerable population of
NK cells was double positive for IFN-g and CD107a (Fig. 2D); by
18 h, cells coexpressing IFN-g and CD25 (Fig. 2E), together with
a small, but statistically significant, population of triple-positive
NK cells (Fig. 2F), were detectable. Importantly, influenza virus
stimulation in the presence of as little as 0.75 ng/ml IL-15 was
almost as effective at inducing polyfunctional NK cells as much
higher concentrations of a combination of IL-12 and IL-18 (5 and
50 ng/ml, respectively, Supplemental Fig. 2A–C). Polyfunctionality
of NK cells was also evident from the statistically significant cor-
relation between expression of the different functional markers by
NK cells cultured with H3N2 plus IL-15 compared with those
cultured with H3N2 alone (Supplemental Fig. 2D–I). Overall,
therefore, IL-15 significantly increased the frequency of poly-
functional NK cells responding to influenza virus.
FIGURE 1. Nanogram concentrations of IL-15 boost and sustain functional NK cell responses to H3N2. PBMCs were cultured in vitro for 6, 9, and
18 h in medium alone (unstimulated; n = 12), IL-15 alone (n = 12), H3N2 (n = 62), or H3N2 plus IL-15 (n = 62). (A) NK cells are gated as CD56+CD32
lymphocytes. Flow cytometry gating strategy for NK cell CD107a (B), IFN-g (C), and CD25 (D) responses after an 18-h in vitro culture in one
representative individual. Numbers shown are the percentage of total NK cells positive for each marker. Graphs show the percentage of the total NK cell
population expressing CD107a (E), IFN-g (F), or CD25 (G). Data are median and 95% confidence interval. ***p , 0.001, ****p , 0.0001 H3N2 alone
versus H3N2 plus IL-15 by the Wilcoxon signed-rank test.
The Journal of Immunology 3
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IL-15 enhances in vitro production of myeloid cell–derived
cytokines
Because NK cells respond to cytokines released from activated
accessory cells, such as DCs and monocytes, supernatants were
collected from cultures at 18 h, and cytokine concentrations were
measured by Luminex. H3N2 alone induced secretion of significant
concentrations of IL-12 (p70), IFN-a2, IFN-g, GM-CSF, IL-1b,
TNF-a, and IL-10 (Fig. 3A–G). However, addition of low con-
centrations of IL-15 to H3N2 resulted in further significant in-
creases in the secretion of all of these cytokines, with the
exception of IL-10 (Fig. 3G). IL-15–mediated enhancement of IL-
12 secretion was observed in 42 of 73 donors (57.5%), with an
average 2.1-fold increase in these individuals (Fig. 3A). IL-15
costimulation increased IFN-a2 secretion in 66% of individuals
compared with H3N2 alone, with a median 1.2-fold increase
(Fig. 3B), as well as enhanced IFN-g by an average of 5.6-fold
(Fig. 3C), consistent with IL-15 boosting of NK cell IFN-g re-
sponses (Fig. 1). In contrast, IL-15 alone induced only modest
increases in IFN-g and GM-CSF production (median increase of
only 8.18 pg/ml for IFN-g and an increase in GM-CSF in only 3 of
FIGURE 2. IL-15 enhances NK cell polyfunctionality. CD107a and CD25 expression of IFN-g–secreting NK cells was gated at 6 h (A), 9 h (B), or 18 h
(C). Plots show NK cell function in one representative donor; number is the percentage of the parent population after stimulation with H3N2 plus IL-15.
Frequencies of IFN-g+CD107a+ double-positive (D), IFN-g+CD25+ double-positive (E), and IFN-g+CD25+CD107a+ triple-positive (F) NK cells, after Ag
stimulation with IL-15 (gray) or without IL-15 (black), at each time point (n = 62). Graphs are box-and-whisker plots with 10–90th percentiles. (G) Median
distribution of triple-, double-, and single-positive NK cells after stimulation with H3N2 alone or H3N2 with IL-15 for 18 h are shown as pie charts as
the percentage of total NK cells (pie slice) and the proportion expressing each marker (pie arc). ****p , 0.0001, Wilcoxon signed-rank test.
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20 donors) compared with unstimulated cells (Fig. 3C, 3D), and
IL-15 alone had no effect on IL-12 (p70), IFN-a2, IL-1b, TNF-a,
or IL-10 secretion (Fig. 3A, 3B, 3E–G).
In the presence of H3N2 and IL-15, the percentage of NK cells
producing IFN-g at 18 h was significantly correlated with the
secreted concentrations of IL-12 and type I IFN (Fig. 3H–M).
However, there was no enhanced correlation between NK cells
producing IFN-g and GM-CSF, TNF-a, or IL-1b with IL-15
(GM-CSF: r = +0.385, r = +0.391 with IL-15; TNF-a: r = +0.231,
r = +0.285 with IL-15; IL-1b: r = +0.197, r = +0.331 with IL-15),
suggesting that IL-12 and/or IFN-a2 might be driving the en-
hanced NK cell IFN-g response. In summary, IL-15 dramatically
enhances the secretion of myeloid cell–derived cytokines, and the
secretion of two of these cytokines (IL-12 and IFN-a2) is strongly
correlated with NK cell function.
IL-12 is critical for IL-15–mediated enhancement of NK cell
responses and generation of polyfunctional NK cells
Because IL-12 and IFN-a2 were induced by coculturing PBMCs
with H3N2 and IL-15, and because enhanced NK cell function
was correlated with the concentrations of these two monokines,
we tested the hypothesis that the effects of IL-15 on NK cells were
mediated via IL-12 and/or type I IFNs. Neutralizing Abs against
IL-12, IFN-abR2, and IL-2 were added to cultures stimulated
with H3N2 (with and without IL-15) for 6, 9, and 18 h. All three
NK cell functional responses were reduced in the presence of
FIGURE 3. IL-15 enhances in vitro production of myeloid cell–derived cytokines. Supernatants were collected from whole PBMCs cultured with
medium (n = 20), IL-15 (n = 20), H3N2 (n = 73), or H3N2 with IL-15 (n = 73) for 18 h, and concentrations of IL-12p70 (A), IFN-a2 (B), IFN-g (C),
GM-CSF (D), IL-1b (E), TNF-a (F), and IL-10 (G) were determined by Luminex technology. The correlation between NK cell IFN-g production was
determined by intracellular cytokine staining, and the concentration of IL-12 (p70) (H and K), IFN-a2 (I and L), and IFN-g (J and M) was determined
by Luminex after stimulation with H3N2 (H–J) or H3N2 with IL-15 (K–M). (A–G) Graphs are before-and-after plots. *p , 0.05, ****p , 0.0001,
Wilcoxon signed-rank test. (H–M) Correlations were measured by linear regression, with statistical significance determined as a p value , 0.05.
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blocking Ab to IL-12 by 18 h (Fig. 4A–F), as well as at the earlier
time point of 9 h (data not shown); in particular, the frequency of
CD107a- or IFN-g–producing cells induced by H3N2 plus IL-15
was reduced to that observed in the absence of IL-15 (Fig. 4A–E).
Degranulation was also dependent, in part, on type I IFNs, be-
cause blockade of the IFN-abR2 receptor led to a partial reduc-
tion in CD107a expression in cultures treated or not with IL-15
(Fig. 4A, 4D). Blocking IL-2 also reduced CD107a upregulation
after H3N2 stimulation, irrespective of the presence or absence of
IL-15 (Fig. 4A, 4D). However, although anti–IL-2 reduced the NK
cell IFN-g response to H3N2, no such reduction was seen in the
response to H3N2 plus IL-15, suggesting that IL-15 may be
substituting for IL-2 in this assay.
In addition to reducing the overall frequencies of CD107a+,
IFN-g+, and CD25+ NK cells, IL-12 blockade had a marked
effect on the induction of polyfunctional NK cells. IL-12 neutrali-
zation reduced the frequencies of double- and triple-positive NK
cells to the levels observed without IL-15 (Fig. 4G–J). These data
suggest that the heightened NK cell response to H3N2 and the
generation of polyfunctional NK cells in response to IL-15 are de-
pendent on accessory cell IL-12. Furthermore, correlations between
different NK cell functional markers (as seen in Supplemental
Fig. 2D–I) are also seen when NK cells are stimulated with
high concentrations of exogenous IL-12 and IL-18 (data not
shown). Stimulation of purified NK cells with H3N2 alone or with
IL-15 induced no significant activation, confirming an accessory
cell requirement for the virus-induced response and IL-15–medi-
ated enhancement (IFN-g percentage at 18 h: H3N2 median
0.29%, IQR 0.25–0.368%, H3N2+IL-15 median 0.465%, IQR
0.308–0.84; CD107a percentage at 18 h: H3N2 median 0.93%, IQR
0.605–1.293%, H3N2+IL-15 median 1.68%, IQR 0.75–2.475%).
IL-15 enhances IL-12 production by mDCs
To determine the source of IL-15–induced IL-12 within PBMCs,
stimulations were performed with H3N2 in the presence or ab-
sence of IL-15 for 18 h, and cells were stained for DC/monocyte
phenotypic markers and for intracellular IL-12(p40). DC pop-
ulations were gated as lineage2CD142HLA-DR+ cells and further
split into CD1232CD11c+ mDC and CD123+CD11c2 plasmacy-
toid DC (pDC) populations. The majority of IL-12–producing
cells were mDCs rather than pDCs, classical (CD14+CD162)
monocytes, or nonclassical (CD142CD16+) monocytes (Fig. 5A).
Up to 3.1% of mDCs expressed IL-12 in response to H3N2, and a
significantly higher proportion (4.5%) were IL-12+ with the
combination of H3N2 and IL-15 (a median 1.9-fold increase)
(Fig. 5A). Furthermore, IL-15–mediated enhancement of IL-12
production was observed only in DCs and was associated with
increased expression (MFI) of CD86 (Fig. 5B). Little to no IL-12
was detected in unstimulated mDCs or in those treated with IL-15
alone (Fig. 5C). Of the 14 individuals tested, 8 (57.1%) showed an
increase in IL-12 production by mDCs with H3N2 plus IL-15
compared with H3N2 alone, corresponding with the proportion
of responders determined by Luminex detection of IL-12 in su-
pernatant (Fig. 5D). Among these eight responders, there was also
an increase in the MFI of IL-12 staining of mDCs cultured with
H3N2 plus IL-15 compared with H3N2 alone (Fig. 5E). These
data suggest that IL-15 potentiates NK cell responses to H3N2 by
enhancing maturation (CD86 expression) and IL-12 production
specifically from mDCs.
Enhancement in NK cell function by IL-15 is observed in
HCMV-seropositive and -seronegative individuals
We (19, 20), and other investigators (21, 22) have reported
altered NK cell functions in HCMV-seropositive individuals.
HCMV-seropositive individuals also respond less well to exoge-
nous cytokines and vaccine Ags (including H3N2), and this is only
partially explained by accelerated NK cell differentiation (19, 20).
We again observed lower NK cell CD107a, IFN-g, and CD25
responses to H3N2 among HCMV-seropositive donors than
among HCMV-seronegative donors (Fig. 6). Low concentrations
of IL-15 enhanced the responses of HCMV-seropositive and
-seronegative subjects but could not fully restore the NK cell re-
sponse of HCMV-seropositive subjects to the level seen in HCMV-
seronegative subjects (Fig. 6A–C). Interestingly, however, IL-15
completely restored the IFN-g response of CD56bright and
CD56dimCD572 NK cells, but not CD56dimCD57+ cells, in
HCMV-seropositive individuals (Fig. 6E, 6H). This suggests that
IL-15 preferentially affects immature NK cells, normalizing their
IFN-g response to H3N2 to the level seen in HCMV-seronegative
individuals. With the exception of a reduced IFN-g response,
which may be accounted for by reduced production from NK cells
in seropositive individuals, there was no difference in the in vitro
production of lymphoid or myeloid cell–derived cytokines in re-
sponse to H3N2 between HCMV-seropositive and -seronegative
donors, irrespective of the presence or absence of IL-15
(Supplemental Fig. 3).
Discussion
Many studies of the effect of IL-15 on NK cell activation focus on
IL-15 trans-presentation or direct activation of NK cells with high
concentrations of IL-15 (typically between 5 and 50 ng/ml) in
combination with other cytokines (5, 10). Moreover, the synergy
between cytokines and pathogen-derived signals for NK cell ac-
tivation has typically been studied only for high concentrations of
cytokines acting on isolated NK cells, precluding consideration of
the potential indirect effects of the pathogen, the cytokines, or
both. To characterize more deeply the potential for synergy be-
tween IL-15 and pathogen-derived signals in NK cell activation,
we have conducted a comprehensive analysis of NK cell CD107a,
IFN-g, and CD25 expression and myeloid cell–derived cytokine
secretion in response to H3N2 in the presence or absence of an
extremely low concentration of IL-15.
Low concentrations of IL-15 enhanced the innate cytokine
response to influenza virus, and this increased cytokine (primarily
IL-12) was associated with potentiation of NK cell function. Im-
portantly, the concentrations of endogenous IL-12 induced by this
synergistic interaction between influenza virus and IL-15 are of the
same order of magnitude as the lowest concentrations of IL-12 that
we have previously shown to effectively synergize with IL-15 and
other common g-chain family cytokines for NK cell activation
in vitro (13). The measured concentration of IL-12 and the con-
centration of IL-15 used in this study are $5-fold lower than the
described effective concentrations for NK cell activation with
single cytokines and may be more physiologically relevant than
the higher concentrations previously studied in vitro. The low
in vitro concentration used in this study is within the range for the
maximal serum concentration achieved therapeutically in patients
with metastatic malignant melanoma or renal cancer after a low-
dose transfusion of 0.3 mg/kg/day recombinant human IL-15 and
which resulted in increases in innate cytokines (23).
In this article, we have shown that IL-15 preferentially enhances
virus-induced mDC maturation (measured by upregulation of
costimulatory marker CD86), as well as cytokine secretion,
compared with other DC subsets and monocytes and that, together,
this heightens and sustains NK cell activation. This role for mDCs
is fully in line with the known pathogen-recognition repertoire and
cytokine-production profile of mDCs (24, 25). Similarly, the
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essential role for DC-derived IL-12 in NK cell activation is in line
with published data, including data showing that IL-12 synergizes
with specific Ab for NK cell–mediated Ab-dependent cell–medi-
ated cytotoxicity of tumors (26, 27), that NK cell activation by
HPV-like particle–matured DCs is reversed by IL-12–blocking
Abs (28), and that exogenous IL-12 can restore NK cell function
FIGURE 4. IL-12 is critical for IL-15–mediated enhancement of NK cell responses and generation of polyfunctional NK cells. PBMCs were cultured for
6, 9, and 18 h with H3N2 (A–C) and H3N2 plus IL-15 (D–F) in the presence of IL-12–, IFN-abR2–, or IL-2–blocking Ab or the appropriate isotype control.
Graphs show CD107a (A and D), IFN-g (B and E), and CD25 (C and F) responses after an 18-h culture, and frequencies of IFN-g+CD107a+ (G), IFN-g+
CD25+ (H) double-positive and IFN-g+CD25+CD107a+ triple-positive (I) NK cells after 9 h (peak of IFN-g response) or 18 h (peak of CD25 response)
(n = 11). Graphs are box-and-whisker plots with 10–90th percentile. (J) Median distributions of triple-, double-, and single-positive NK cells after
stimulation with H3N2 and IL-15 for 18 h are shown as the percentage of total NK cells (pie slice) and the proportion expressing each marker (pie arc).
*p , 0.05, **p , 0.01, ***p , 0.001, Wilcoxon signed-rank test.
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in HIV-exposed, but uninfected, infants (29). Interestingly, IL-15
synergizes well in vitro with IL-12 and IL-18 but not with other
IL-2Rg-chain–dependent cytokines, including IL-2 and IL-21,
suggesting some redundancy between the latter pathways (13).
This is also consistent with our observation that neutralization of
endogenous IL-2 did not reduce NK cell IFN-g in response to
H3N2 and IL-15.
Enhancement of NK cell function by IL-15 is well established
(30). IL-15 has also been reported to enhance DC maturation
(measured by upregulation of CD40, CD86, and MHC class II ex-
pression) in mice (17, 31). In line with our observations in humans,
DCs cultured with HPV-like particle matured more efficiently in the
presence of IL-15, and this correlated with enhanced NK cell acti-
vation and killing of HPV-infected tumor cells (17). However, the role
of IL-15 enhancement of IL-12 production by peripheral DCs has not
been previously appreciated or linked to enhanced NK cell responses.
Interestingly, one study demonstrated that IL-15 enhancement of
IL-12 secretion by a PMA-activated U937 monocytic cell line was
FIGURE 5. IL-15 enhances IL-12 production by mDCs. PBMCs were cultured with H3N2 or H3N2 with IL-15 (n = 14) for 18 h, and cells were stained for DC
and monocyte phenotypic markers and intracellular IL-12. Single live cells were further gated as lineage (CD3, CD19, CD56) negative, classical (CD14+CD162),
and nonclassical (CD142CD16+) monocytes, all CD14+ and CD142 cells, all CD142HLA-DR+ DCs, mDCs (CD1232CD11c+), and pDCs (CD123+CD11c2).
IL-12+ events (A) and CD86 MFI (B) for each cell type was gated using fluorescence minus one controls and shown as one data point per donor; the horizontal line
represents the median. (C) Flow cytometry gating strategy for IL-12+ mDCs is shown in one representative individual; numbers denote the percentage
of IL-12+ mDCs. Before-and-after plots show the percentage of mDCs expressing IL-12 for each individual when stimulated with H3N2 +/2 IL-15 (D)
and the corresponding IL-12 MFI for each responder and nonresponder with IL-15 costimulation (E). *p , 0.05, Wilcoxon signed-rank test.
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associated with increased ability to kill intracellular Leishmania
parasites, suggestive of a potential role for such mechanisms in
protection against infection (32).
The cytotoxic and cytokine-producing roles of NK cells have
traditionally been ascribed to distinct NK cell subsets (CD56dim and
CD56bright, respectively), and this dichotomy has rather obscured the
potential for NK cells to perform both functions simultaneously
(i.e., to be polyfunctional). Nevertheless, polyfunctional CD56dim
CD62L+ NK cells (with dual ability to produce IFN-g and become
cytotoxic) can be induced by stimulation with high concentrations
(50 ng/ml) of IL-12 and IL-18 (33), and TLR stimulation induced
polyfunctional NK cells (expressing two or more of CD107a, IFN-g,
and TNF-a) in HIV-1–exposed seronegative, but not seropositive,
individuals (34). We defined polyfunctionality as simultaneous ex-
pression of two or more of IFN-g, CD107a, and CD25 by any NK
cell subset; no polyfunctional cells were induced by IL-15 alone, and
very few were detected in response to influenza virus alone. However,
stimulation with IL-15 and virus induced significant numbers of
double- and triple-positive NK cells, suggesting that synergy (likely at
the level of mDCs) between IL-15 and pattern recognition receptor
signaling may be necessary for the induction of polyfunctional NK
cells. This may be due, in part, to the dependence of NK cells on IL-
12 to drive IFN-g production and on IFN-a and IL-15 to drive cy-
totoxicity (2, 35).
Our observation that IL-15 restored the impaired responses of
HCMV-seropositive individuals only among the less differentiated
CD56bright and CD56dimCD572 NK cell subsets, as well as that
(with the exception of IFN-g production) there were no differ-
ences in cytokine production by PBMCs from HCMV-seropositive
and -seronegative donors, suggests that polyfunctionality may
arise from broadening the effector function of less mature NK
subsets rather than any effect on mature NK subsets. This effect is
entirely consistent with IL-12–mediated IL-15 enhancement of
NK cell responses, IL-12R expression, and, therefore, respon-
siveness being progressively lost during NK cell differentiation
and in adaptive NK cell subsets (18, 36). Moreover, these data
suggest that reduced NK cell responses in HCMV-seropositive
individuals are not due to an accessory cell defect but may
result from intrinsic changes in more-differentiated NK cells
(18, 22). This hypothesis, that IL-15 broadens the functional
response of immature NK cells, is further supported by evi-
dence that degranulation and IFN-g and TNF-a production
from CD56bright NK cells are potently enhanced by exposure to
multiple myeloma or acute myeloid leukemia target cells after
in vivo therapy with the IL-15R agonist ALT803 (37). The use
of an IL-15/IL-15Ra superagonist may further boost NK cell
responses to H3N2; however, this would be expected to act on
NK cells directly, because IL-15 is already complexed to its
receptor, therefore potentially bypassing accessory cell–de-
pendent effects.
In summary, we have revealed an unexpected impact of very
low concentrations of IL-15 on the production of cytokines, in
FIGURE 6. Enhancement in NK cell function by IL-15 is observed in HCMV-seropositive and -seronegative individuals. HCMV serostatus for each
individual was determined (n = 35 seropositive and n = 38 seronegative). CD107a (A), IFN-g (B), and CD25 (C) expression within each group after
stimulation with H3N2 or H3N2 plus IL-15 for 6, 9, or 18 h. NK cell responses attributed to each differentiation subset determined by the expression of
CD56 and CD57, CD56bright, CD56dimCD572, and CD56dimCD57+ were analyzed (flow cytometry gating strategy in Supplemental Fig. 1A). Graphs show
median with 95% confidence interval. CD107a (D and G), IFN-g (E and H), and CD25 (F and I) expression within each subset is shown for
HCMV-seropositive and -seronegative individuals; only the peak time point for each response is shown. Each dot represents an individual donor; the
horizontal line represents the median. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001, H3N2 versus H3N2 plus IL-15, Wilcoxon signed-rank test
(A–C), unpaired Mann–Whitney U test (D–I). ns, not significant.
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particular IL-12 from mDCs, which, in turn, plays a vital role in
boosting NK cell responses to influenza virus (summarized in
Supplemental Fig. 4). In addition to increasing the overall fre-
quencies of responding NK cells, IL-15 promotes the generation
of polyfunctional NK cells. These studies suggest that the use of
very low dose IL-15 may be a strategy for enhancing and
broadening NK cell effector function in immunotherapy and in
enhancing vaccine responses.
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